Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline

Ton Kuijpers, Frederick A. Spencer, Reed A.C. Siemieniuk, Per O. Vandvik, Catherine M. Otto, Lyubov Lytvyn, Hassan Mir, Albert Y. Jin, Veena Manja, Ganesan Karthikeyan, Elke Hoendermis, Janet Martin, Sebastian Carballo, Martin O'Donnell, Trond Vartdal, Christine Baxter, Bray Patrick-Lake, Joanie Scott, Thomas Agoritsas, Gordon Guyatt

Research output: Contribution to journalArticle

32 Scopus citations
Original languageEnglish (US)
Article numberk2515
JournalBMJ (Online)
Volume362
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kuijpers, T., Spencer, F. A., Siemieniuk, R. A. C., Vandvik, P. O., Otto, C. M., Lytvyn, L., Mir, H., Jin, A. Y., Manja, V., Karthikeyan, G., Hoendermis, E., Martin, J., Carballo, S., O'Donnell, M., Vartdal, T., Baxter, C., Patrick-Lake, B., Scott, J., Agoritsas, T., & Guyatt, G. (2018). Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ (Online), 362, [k2515]. https://doi.org/10.1136/bmj.k2515